Intrauterine Device Extraction Medication

1. Hatcher RA,Trussell J, Nelson AL, Cates W, Stewart F, Kowal D. Contraceptive Technology. 19. New York, NY: Ardent Media; 2007.

2. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23. 2010 Aug. 1-44. [Medline].

3. Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception. 2009 Jan. 79(1):5-14. [Medline].

4. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011 May. 117(5):1105-13. [Medline].

5. Skyla (levonorgestrel-releasing intrauterine system) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc. January 2013. Available at [Full Text].

6. Mirena levonorgestrel-releasing intrauterine system [package insert]. Berlex. 2003. Available at [Full Text].

7. Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept. 1995 Jun. 11(2):85-95. [Medline].

8. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril. 1984 Jan. 41(1):52-5. [Medline].

9. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999 Nov. 181(5 Pt 1):1263-9. [Medline].

10. Baveja R, Bichille LK, Coyaji KJ, Engineer AD, Gogoi MP, Hazra MN. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception. 1989 Jan. 39(1):37-52. [Medline].

11. Paragard T380A intrauterine copper contraceptive [package insert]. FEI Products. 2003. Available at [Full Text].

12. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception. 1992 Dec. 46(6):575-84. [Medline].

13. Alnakash AH. Influence of IUD perceptions on method discontinuation. Contraception. 2008 Oct. 78(4):290-3. [Medline].

14. El-Tagy A, Sakr E, Sokal DC, Issa AH. Safety and acceptability of post-abortal IUD insertion and the importance of counseling. Contraception. 2003 Mar. 67(3):229-34. [Medline].

15. Darney PD, Klaisle CM. Contraception-associated menstrual problems: etiology and management. Dialogues Contracept. 1998 Spring. 5(5):1-6. [Medline].

16. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol. 2011 Jul. 118(1):184-96. [Medline].

17. World Health Organization: Medical Eligibility Criteria for Contraceptive Use. 2009.

18. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep. 2010 Jun 18. 59:1-86. [Medline].

19. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992 Mar 28. 339(8796):785-8. [Medline].

20. Beerthuizen RJ. Pelvic inflammatory disease in intrauterine device users. Eur J Contracept Reprod Health Care. 1996 Sep. 1(3):237-43. [Medline].

21. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006 Feb. 73(2):145-53. [Medline].

22. Ozgun MT, Batukan C, Serin IS, Ozcelik B, Basbug M, Dolanbay M. Surgical management of intra-abdominal mislocated intrauterine devices. Contraception. 2007 Feb. 75(2):96-100. [Medline].

23. Verma U, Astudillo-Davalos FE, Gerkowicz SA. Safe and cost-effective ultrasound guided removal of retained intrauterine device: our experience. Contraception. 2015 Feb 21. [Medline].

24. Swenson C, Royer PA, Turok DK, Jacobson JC, Amaral G, Sanders JN. Removal of the LNG IUD when strings are not visible: a case series. Contraception. 2014 Sep. 90(3):288-90. [Medline].

25. Markovitch O, Klein Z, Gidoni Y, Holzinger M, Beyth Y. Extrauterine mislocated IUD: is surgical removal mandatory?. Contraception. 2002 Aug. 66(2):105-8. [Medline].

26. Heinberg EM, McCoy TW, Pasic R. The perforated intrauterine device: endoscopic retrieval. JSLS. 2008 Jan-Mar. 12(1):97-100. [Medline].

27. Haimov-Kochman R, Amsalem H, Adoni A, Lavy Y, Spitz IM. Management of a perforated levonorgestrel-medicated intrauterine device--a pharmacokinetic study: case report. Hum Reprod. 2003 Jun. 18(6):1231-3. [Medline].

28. Adoni A, Ben Chetrit A. The management of intrauterine devices following uterine perforation. Contraception. 1991 Jan. 43(1):77-81. [Medline].

29. Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception. 1999 Sep. 60(3):155-60. [Medline].

Sarah Hagood Milton, MD Resident Physician, Department of Obstetrics and Gynecology, Virginia Commonwealth University Health System

Disclosure: Nothing to disclose.

Nicole W Karjane, MD Associate Professor, Department of Obstetrics and Gynecology, Virginia Commonwealth University Medical Center

Nicole W Karjane, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Professors of Gynecology and Obstetrics, North American Society for Pediatric and Adolescent Gynecology

Disclosure: Received income in an amount equal to or greater than $250 from: Merck<br/>Served as Nexplanon trainer for: Merck.

Christine Isaacs, MD Associate Professor, Department of Obstetrics and Gynecology, Division Head, General Obstetrics and Gynecology, Medical Director of Midwifery Services, Virginia Commonwealth University School of Medicine

Christine Isaacs, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of